JPMorgan Chase Reaffirms Overweight Rating for AstraZeneca (AZN)

JPMorgan Chase restated their overweight rating on shares of AstraZeneca (LON:AZN) in a report published on Tuesday morning, Marketbeat reports. JPMorgan Chase currently has a GBX 5,500 ($74.61) target price on the biopharmaceutical company’s stock.

Several other equities research analysts also recently weighed in on the company. Jefferies Group increased their price target on AstraZeneca from GBX 5,600 ($75.96) to GBX 5,950 ($80.71) and gave the stock a buy rating in a report on Monday. Barclays set a GBX 6,500 ($88.17) price target on AstraZeneca and gave the stock a buy rating in a report on Friday, May 11th. Shore Capital reissued a hold rating on shares of AstraZeneca in a report on Friday, May 11th. Credit Suisse Group reissued an outperform rating on shares of AstraZeneca in a report on Friday, May 4th. Finally, Goldman Sachs set a GBX 3,750 ($50.87) target price on AstraZeneca and gave the company a sell rating in a report on Tuesday, April 24th. Four analysts have rated the stock with a sell rating, six have issued a hold rating and fourteen have issued a buy rating to the company. AstraZeneca currently has a consensus rating of Hold and an average target price of GBX 5,255.78 ($71.29).

Shares of AstraZeneca opened at GBX 5,208 ($70.65) on Tuesday, according to Marketbeat. AstraZeneca has a 1-year low of GBX 4,260 ($57.79) and a 1-year high of GBX 5,520 ($74.88).

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with's FREE daily email newsletter.

Leave a Reply